Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Ovarian Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Fallopian Tube Neoplasms 4Adenocarcinoma Of Esophagus 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Pancreatic Cystic Neoplasm 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Locally Advanced Cervical Adenocarcinoma 1Laryngeal Neoplasms 1

Interventions

pembrolizumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 11Biopsy 11Paclitaxel 8Carboplatin 8trastuzumab deruxtecan 6Pemetrexed 6Nivolumab 6Irinotecan 6Fulvestrant 6Bevacizumab 6Radiosurgery 5Leucovorin 5Gemcitabine 5Fluorouracil 5Cetuximab 5palbociclib 4Oxaliplatin 4Letrozole 4Cisplatin 4olaparib 3durvalumab 3Taxes 3Ipilimumab 3Docetaxel 3Capecitabine 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Taxes × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡